{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:02:30Z","timestamp":1790276550995,"version":"4.1.0"},"reference-count":119,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hypertension is one of the strongest modifiable cardiovascular risk factors, affecting an increasing number of people worldwide. Apart from poor medication adherence, the low efficacy of some therapies could also be related to inter-individual genetic variability. Genetic studies of families revealed that heritability accounts for 30% to 50% of inter-individual variation in blood pressure (BP). Genetic factors not only affect blood pressure (BP) elevation but also contribute to inter-individual variability in response to antihypertensive treatment. This article reviews the recent pharmacogenomics literature concerning the key classes of antihypertensive drugs currently in use (i.e., diuretics, \u03b2-blockers, ACE inhibitors, ARB, and CCB). Due to the numerous studies on this topic and the sometimes-contradictory results within them, the presented data are limited to several selected SNPs that alter drug response. Genetic polymorphisms can influence drug responses through genes engaged in the pathogenesis of hypertension that are able to modify the effects of drugs, modifications in drug\u2013gene mechanistic interactions, polymorphisms within drug-metabolizing enzymes, genes related to drug transporters, and genes participating in complex cascades and metabolic reactions. The results of numerous studies confirm that genotype-based antihypertension therapies are the most effective and may help to avoid the occurrence of major adverse events, as well as decrease the costs of treatment. However, the genetic heritability of drug response phenotypes seems to remain hidden in multigenic and multifactorial complex traits. Therefore, further studies are required to analyze all associations and formulate final genome-based treatment recommendations.<\/jats:p>","DOI":"10.3390\/ijms21134709","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T02:44:25Z","timestamp":1593657865000},"page":"4709","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Pharmacogenomics of Hypertension Treatment"],"prefix":"10.3390","volume":"21","author":[{"given":"Jacek","family":"Rysz","sequence":"first","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Franczyk","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Rysz-G\u00f3rzy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Rehabilitation, Medical University of Lodz, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3322-5655","authenticated-orcid":false,"given":"Anna","family":"Gluba-Brz\u00f3zka","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"ref_1","first-page":"341","article-title":"Pharmacogenomics and Hypertension: Current Insights","volume":"12","author":"Pereira","year":"2019","journal-title":"Pharmgenomics Pers. Med."},{"key":"ref_2","unstructured":"(2020, February 15). Heart Disease and Stroke Statistics\u20142019 Update. Available online: https:\/\/professional.heart.org\/professional\/ScienceNews\/UCM_503383_Heart-Disease-and-Stroke-Statistics---2019-Update.jsp."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: Analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4172\/2153-0645.1000126","article-title":"Benefits of Pharmacogenetics in the Management of Hypertension","volume":"5","author":"Torrellas","year":"2014","journal-title":"J. Pharmacogenomics Pharmacoproteomics"},{"key":"ref_5","first-page":"1","article-title":"Hypertension among adults in the United States; 2009\u20132010","volume":"107","author":"Yoon","year":"2012","journal-title":"NCHS Data Brief"},{"key":"ref_6","first-page":"CD006742","article-title":"Pharmacotherapy for mild hypertension","volume":"8","author":"Diao","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e001521","DOI":"10.1161\/JAHA.114.001521","article-title":"Pharmacogenomics of hypertension: A genome-wide; placebo-controlled cross-over study; using four classes of antihypertensive drugs","volume":"4","author":"Hiltunen","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tig.2012.04.001","article-title":"Genetic basis of blood pressure and hypertension","volume":"28","author":"Padmanabhan","year":"2012","journal-title":"Trends Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1093\/eurheartj\/ehs455","article-title":"Genes for blood pressure: An opportunity to understand hypertension","volume":"34","author":"Ehret","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1161\/CIRCRESAHA.112.300387","article-title":"Advances in blood pressure genomics","volume":"112","author":"Munroe","year":"2013","journal-title":"Circ. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.3109\/07853890.2011.653399","article-title":"Advancing management of hypertension through pharmacogenomics","volume":"44","author":"Johnson","year":"2012","journal-title":"Ann. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fphar.2018.00168","article-title":"Pharmacogenomics of Hypertension and Preeclampsia: Focus on Gene\u2013Gene Interactions","volume":"9","author":"Luizon","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1152\/physrev.00035.2016","article-title":"Towards precision medicine for hypertension: A review of genomic; epigenomic; and microbiomic effects on blood pressure in experimental rat models and humans","volume":"97","author":"Padmanabhan","year":"2017","journal-title":"Physiol. Rev."},{"key":"ref_14","first-page":"e119","article-title":"The Metabolomic Paradigm of Pharmacogenomics in Complex Disorders","volume":"2","author":"Cacabelos","year":"2012","journal-title":"Metabolomics"},{"key":"ref_15","first-page":"112","article-title":"Pharmacogenetics\u2014Challenges and opportunities ahead","volume":"1","author":"Zanger","year":"2010","journal-title":"Front. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10741-018-09765-y","article-title":"Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: A mini review","volume":"24","author":"Johnson","year":"2019","journal-title":"Heart Fail. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.amjmed.2003.08.027","article-title":"Calcium channel blockers: An update","volume":"116","author":"Eisenberg","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.07.026","article-title":"Antihypertensive drugs","volume":"124","author":"Laurent","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/FPC.0b013e32810f2e3c","article-title":"KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR\/Trandolapril STudy (INVEST)","volume":"17","author":"Beitelshees","year":"2007","journal-title":"Pharmacogenet. Genomics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1161\/CIRCGENETICS.110.957654","article-title":"Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetics association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES)","volume":"3","author":"Niu","year":"2010","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1253\/circj.CJ-08-0761","article-title":"Genetic polymorphisms of L-type calcium channel alpha1C and alpha1D subunit genes are associated with sensitivity to the antihypertensive effects of L-type dihydropyridine calcium-channel blockers","volume":"73","author":"Kamide","year":"2009","journal-title":"Circ. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2217\/14622416.7.3.271","article-title":"CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension","volume":"7","author":"Bremer","year":"2006","journal-title":"Pharmacogenomics"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"He, F., Luo, J., Luo, Z., Fan, L., He, Y., Zhu, D., Gao, J., Deng, S., Wang, Y., and Qian, Y. (2013). The KCNH2 genetic polymorphism (1956; C>T) is a novel biomarker that is associated with CCB and alpha;beta-ADR blocker response in EH patients in China. PLoS One, 8.","DOI":"10.1371\/journal.pone.0061317"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/23808993.2018.1420419","article-title":"Pharmacogenomic studies of hypertension: Paving the way for personalized antihypertensive treatment","volume":"3","author":"Eadon","year":"2018","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1161\/CIRCGENETICS.109.857839","article-title":"CACNA1C gene polymorphisms; cardiovascular disease outcomes; and treatment response","volume":"2","author":"Beitelshees","year":"2009","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(97)01029-5","article-title":"Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension","volume":"349","author":"Cusi","year":"1997","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2217\/pgs.13.161","article-title":"Genome-wide response to antihypertensive medication using home blood pressure measurements: A pilot study nested within the homed-BP study","volume":"14","author":"Kamide","year":"2013","journal-title":"Pharmacogenomics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/sj.clpt.6100090","article-title":"Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil","volume":"81","author":"Langaee","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e000473","DOI":"10.1136\/openhrt-2016-000473","article-title":"Amlodipine in hypertension: A first-line agent with efficacy for improving blood pressure and patient outcomes","volume":"3","author":"Fares","year":"2016","journal-title":"Open Heart"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1124\/dmd.113.055400","article-title":"Amlodipine metabolism in human liver microsomes and roles of cyp3a4\/5 in the dihydropyridine dehydrogenation","volume":"42","author":"Zhu","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000258688","article-title":"Cyp3a4 and cyp3a5 polymorphisms and blood pressure response to amlodipine among African American men and women with early hypertensive renal disease","volume":"31","author":"Bhatnagar","year":"2010","journal-title":"Am. J. Nephrol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-200241050-00002","article-title":"How important are gender differences in pharmacokinetics?","volume":"41","author":"Meibohm","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clpt.2006.09.009","article-title":"Effect of Cyp3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects","volume":"80","author":"Kim","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2133\/dmpk.DMPK-13-RG-127","article-title":"ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: A population analysis","volume":"29","author":"Zuo","year":"2014","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/cphy.c130040","article-title":"Classical renin\u2013angiotensin system in kidney physiology","volume":"4","author":"Sparks","year":"2014","journal-title":"Compr. Physiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11892-009-0081-y","article-title":"Pleiotropic effects of inhibitors of the RAAS in the diabetic population: Above and beyond blood pressure lowering","volume":"10","author":"Ismail","year":"2010","journal-title":"Curr. Diab. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/bcpt.12195","article-title":"Effects of angiotensin-converting enzyme inhibition on leptin and adiponectin levels in essential hypertension","volume":"114","author":"Fontana","year":"2014","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2125.2012.04189.x","article-title":"Effects of angiotensin receptor blockers on endothelial nitric oxide release: The role of eNOS variants","volume":"74","author":"Mason","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_41","first-page":"62","article-title":"Endothelial nitric oxide synthase tagSNPs influence the effects of enalapril in essential hypertension","volume":"55\u201356","author":"Lacchini","year":"2016","journal-title":"Nitric Oxide"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.2217\/pgs.14.119","article-title":"Genome-wide association study identifies CAMKID variants involved in blood pressure response to losartan: The SOPHIA study","volume":"15","author":"Frau","year":"2014","journal-title":"Pharmacogenomics"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1161\/HYP.0b013e31825b30f8","article-title":"Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker","volume":"59","author":"Turner","year":"2012","journal-title":"Hypertension"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1365-2265.2007.02971.x","article-title":"Phenotypic consequences of variation across the aldosterone synthase and 11-beta hydroxylase locus in a hypertensive cohort: Data from the MRC BRIGHT study","volume":"67","author":"Freel","year":"2007","journal-title":"Clin. Endocrinol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1161\/01.HYP.33.2.703","article-title":"Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2","volume":"33","author":"Davies","year":"1999","journal-title":"Hypertension"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/hr.2008.36","article-title":"T allele of \u2212344 C\/T polymorphism in aldosterone synthase gene is not associated with resistant hypertension","volume":"32","author":"Lacchini","year":"2009","journal-title":"Hypertens Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0895-7061(02)02256-2","article-title":"Aldosterone synthase (CYP11B2) \u2212344 C\/T polymorphism is related to antihypertensive response: Result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial","volume":"15","author":"Kurland","year":"2002","journal-title":"Am. J. Hypertens."},{"key":"ref_48","first-page":"1173","article-title":"Associations between human aldosterone synthase CYP11B2 (\u2212344T\/C) gene polymorphism and antihypertensive response to valsartan in Chinese patients with essential hypertension","volume":"8","author":"Ji","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0014-2999(02)01766-1","article-title":"Variants of the CYP11B2 gene predict response to therapy with candesartan","volume":"445","author":"Ortlepp","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bcpt.12682","article-title":"Gene-gene interactions among PRKCA.; NOS3 and BDKRB2 polymorphisms affect the antihypertensive effects of enalapril","volume":"120","author":"Luizon","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/HYPERTENSIONAHA.111.00436","article-title":"Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide","volume":"1979","author":"Turner","year":"2013","journal-title":"Hypertension"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00228-012-1326-2","article-title":"eNOS and BDKRB2 genotypes affect the antihypertensive responses to enalapril","volume":"69","author":"Silva","year":"2013","journal-title":"Eur J. Clin Pharmacol"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0895-7061(99)00005-9","article-title":"Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin\u2013angiotensin-aldosterone system in normotensive and hypertensive subjects","volume":"12","author":"Blumenfeld","year":"1999","journal-title":"Am. J. Hypertens."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S0895-7061(03)01011-2","article-title":"Effects of endothelial nitric oxide synthase; alpha-adducin; and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide","volume":"16","author":"Turner","year":"2003","journal-title":"Am. J. Hypertens."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s10528-011-9444-6","article-title":"Gender-specific association between ACE gene I\/D polymorphism and blood pressure response to hydrochlorothiazide in Han Chinese hypertensive patients","volume":"49","author":"Li","year":"2011","journal-title":"Biochem. Genet."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/clpt.2010.315","article-title":"Cardiovascular pharmacogenomics of adrenergic receptor signaling: Clinical implications and future directions","volume":"89","author":"Johnson","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1152\/physiolgenomics.00087.2013","article-title":"S49G and R389G polymorphisms of the beta(1)-adrenergic receptor influence signaling via the cAMPPKA and ERK pathways","volume":"45","author":"Zhang","year":"2013","journal-title":"Physiol. Genomics"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/clpt.2008.139","article-title":"Beta-adrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension","volume":"84","author":"Pacanowski","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1161\/STROKEAHA.116.015936","article-title":"Pharmacogenetic associations of beta1-adrenergic receptor polymorphisms with cardiovascular outcomes in the SPS3 trial (Secondary Prevention of Small Subcortical Strokes)","volume":"48","author":"Magvanjav","year":"2017","journal-title":"Stroke"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0009-9236(03)00068-7","article-title":"Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol","volume":"74","author":"Johnson","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/FJC.0000000000000119","article-title":"Association of common polymorphisms in beta1-adrenergic receptor with antihypertensive response to carvedilol","volume":"64","author":"Si","year":"2014","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.amjms.2017.11.002","article-title":"The association of ADRB1 and CYP2D6 polymorphisms with antihypertensive effects and analysis of their contribution to hypertension risk","volume":"355","author":"Chen","year":"2018","journal-title":"Am. J. Med. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/FPC.0b013e328338e1b8","article-title":"Common genetic variation of beta1-and beta2-adrenergic receptor and response to four classes of antihypertensive treatment","volume":"20","author":"Suonsyrja","year":"2010","journal-title":"Pharmacogenet. Genomics"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2217\/pgs.09.158","article-title":"Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension","volume":"11","author":"Filigheddu","year":"2010","journal-title":"Pharmacogenomics"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/HYPERTENSIONAHA.112.198721","article-title":"G protein receptor kinase 4 polymorphisms: Beta-blocker pharmacogenetics and treatment-related outcomes in hypertension","volume":"60","author":"Vandell","year":"2012","journal-title":"Hypertension"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/ncpneph0301","article-title":"Mechanisms of disease: The role of grk4 in the etiology of essential hypertension and salt sensitivity","volume":"2","author":"Felder","year":"2006","journal-title":"Nat. Clin. Pract. Nephrol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/cts.12643","article-title":"Genomic association analysis reveals variants associated with blood pressure response to beta-blockers in European Americans","volume":"2","author":"Singh","year":"2019","journal-title":"Clin. Transl. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Larsson, E., Wahlstrand, B., Hedblad, B., Hedner, T., Kjeldsen, S.E., Melander, O., and Lindahl, P. (2013). Hypertension and genetic variation in endothelial-specific genes. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062035"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1161\/CIRCULATIONAHA.111.064030","article-title":"Endothelial cell-specific FGD5 involvement in vascular pruning defines neovessel fate in mice","volume":"125","author":"Cheng","year":"2012","journal-title":"Circulation"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1161\/ATVBAHA.111.244004","article-title":"FGD5 mediates proangiogenic action of vascular endothelial growth factor in human vascular endothelial cells","volume":"32","author":"Kurogane","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1291\/hypres.29.611","article-title":"Association of sixty-one non-synonymous polymorphisms in forty-one hypertension candidate genes with blood pressure variation and hypertension","volume":"29","author":"Kokubo","year":"2006","journal-title":"Hypertens. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/HYPERTENSIONAHA.115.06345","article-title":"Pharmacogenomic genome-wide meta-analysis of blood pressure response to beta-blockers in hypertensive African Americans","volume":"67","author":"Gong","year":"2016","journal-title":"Hypertension"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2217\/pgs-2016-0204","article-title":"Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responses","volume":"18","author":"Rimpela","year":"2017","journal-title":"Pharmacogenomics"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(00)02526-5","article-title":"Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study","volume":"356","author":"Hansson","year":"2000","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/HJH.0b013e3283536338","article-title":"Pharmacogenetic implications for eight common blood pressure-associated single-nucleotide polymorphisms","volume":"30","author":"Hamrefors","year":"2012","journal-title":"J. Hypertens"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e001404","DOI":"10.1161\/CIRCGENETICS.116.001404","article-title":"Genome-wide prioritization and transcriptomics reveal novel signatures associated with thiazide diuretics blood pressure response","volume":"10","author":"Shahin","year":"2017","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: From bench to byte\u2013an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/clpt.2014.62","article-title":"Impact of CYP2D6 polymorphisms on clinical efficacy and tolerability of metoprolol tartrate","volume":"96","author":"Hamadeh","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1177\/0300060514563151","article-title":"Associations between ADRB1 and CYP2D6 gene polymorphisms and the response to beta-blocker therapy in hypertension","volume":"43","author":"Wu","year":"2015","journal-title":"J. Int. Med. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.clpt.2004.08.020","article-title":"Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension","volume":"76","author":"Zineh","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1586\/erc.10.27","article-title":"Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics","volume":"8","author":"Duarte","year":"2010","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.vph.2005.09.010","article-title":"Pharmacogenetics of antihypertensive treatment","volume":"44","author":"Arnett","year":"2006","journal-title":"Vascul. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1751-7176.2012.00679.x","article-title":"The comparative effectiveness of hydrochlorothiazide and chlorthalidone in an observational cohort of veterans","volume":"14","author":"Lund","year":"2012","journal-title":"J. Clin. Hypertes"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.amjhyper.2005.02.012","article-title":"Demographic; environmental; and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects","volume":"18","author":"Turner","year":"2005","journal-title":"Am. J. Hypertens."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/HYPERTENSIONAHA.109.129171","article-title":"Thiazide effects and adverse effects: Insights from molecular genetics","volume":"1979","author":"Ellison","year":"2009","journal-title":"Hypertension"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e007339","DOI":"10.1161\/JAHA.117.007339","article-title":"Genome wide association study identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients","volume":"7","author":"Singh","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/CRD.0b013e3181c61b52","article-title":"Hydrochlorothiazide versus chlorthalidone in the management of hypertension","volume":"18","author":"Neff","year":"2010","journal-title":"Cardiol Rev."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"718","DOI":"10.5414\/CP201899","article-title":"Effects of ACE and ADD1 gene polymorphisms on blood pressure response to hydrochlorothiazide: A meta-analysis","volume":"51","author":"Choi","year":"2013","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1007\/PL00000731","article-title":"Adducin: Structure; function and regulation","volume":"57","author":"Matsuoka","year":"2000","journal-title":"Cell Mol. Life Sci."},{"key":"ref_91","unstructured":"Townsend, R.R. (2019, October 15). Major Side Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers. Available online: https:\/\/www.uptodate.com\/contents\/search."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1161\/01.HYP.0000057010.27011.2C","article-title":"ACE and alpha-adducin polymorphism as markers of individual response to diuretic therapy","volume":"41","author":"Sciarrone","year":"2003","journal-title":"Hypertension"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/ajh.2008.343","article-title":"Renin-angiotensin system and alpha-adducin gene polymorphisms and their relation to responses to antihypertensive drugs: Results from the GENRES study","volume":"22","author":"Suonsyrja","year":"2009","journal-title":"Am. J. Hypertens"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1161\/CIRCULATIONAHA.104.504639","article-title":"Pharmacogenetic association of the angiotensin-converting enzyme insertion\/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: The Genetics of Hypertension-Associated Treatment (GenHAT) study","volume":"111","author":"Arnett","year":"2005","journal-title":"Circulation"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1161\/hy0202.103065","article-title":"Alpha-adducin 460Trp allele is associated with erythrocyte Na transport rate in North Sardinian primary hypertensives","volume":"39","author":"Glorioso","year":"2002","journal-title":"Hypertension"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2217\/pgs.10.203","article-title":"SNPs in genes encoding G proteins in pharmacogenetics","volume":"12","author":"Klenke","year":"2011","journal-title":"Pharmacogenomics"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/ng0198-45","article-title":"Association of a human G-protein beta3 subunit variant with hypertension","volume":"18","author":"Siffert","year":"1998","journal-title":"Nat. Genet."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/01.HYP.37.2.739","article-title":"C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic","volume":"37","author":"Turner","year":"2001","journal-title":"Hypertension"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Adeyemo, A., Gerry, N., Chen, G., Herbert, A., Doumatey, A., Huang, H., Zhou, J., Lashley, K., Chen, Y., and Christman, M. (2009). A genome-wide association study of hypertension and blood pressure in African Americans. PLoS Genet., 5.","DOI":"10.1371\/journal.pgen.1000564"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng.834","article-title":"Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in East Asians","volume":"43","author":"Kato","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e006522","DOI":"10.1161\/JAHA.117.006522","article-title":"Genetic variants associated with uncontrolled blood pressure on thiazide diuretic\/beta-blocker combination therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) trials","volume":"6","author":"Magvanjav","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_102","first-page":"257","article-title":"Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression","volume":"13","author":"Duarte","year":"2013","journal-title":"Pharm J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1161\/HYPERTENSIONAHA.107.104273","article-title":"Genomic association analysis suggests chromosome 12 locus influencing antihypertensive response to thiazide diuretic","volume":"52","author":"Turner","year":"2008","journal-title":"Hypertension"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ahj.2008.11.018","article-title":"Pharmacogenomics of antihypertensive drugs: Rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study","volume":"157","author":"Johnson","year":"2009","journal-title":"Am. Heart J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.116.08267","article-title":"Genome-wide and gene-based meta-analyses identify novel loci influencing blood pressure response to hydrochlorothiazide","volume":"69","author":"Salvi","year":"2017","journal-title":"Hypertension"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/00004872-200405000-00014","article-title":"Association of G-protein-coupled receptor kinase 4 haplotypes, but not HSD3B1 or PTP1B polymorphisms, with essential hypertension","volume":"22","author":"Speirs","year":"2004","journal-title":"J. Hypertens."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/ajh.2009.3","article-title":"Steroid biosynthesis and renal excretion in human essential hypertension: Association with blood pressure and endogenous ouabain","volume":"22","author":"Tripodi","year":"2009","journal-title":"Am. J. Hypertens."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1530\/EJE-10-0428","article-title":"Association of HSD3B1 and HSD3B2 gene polymorphisms with essential hypertension; aldosterone level; and left ventricular structure","volume":"163","author":"Shimodaira","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0006-291X(02)00234-6","article-title":"Polymorphism in exon 4 of the human 3 beta-hydroxysteroid dehydrogenase type I gene (hsd3b1) and blood pressure","volume":"293","author":"Rosmond","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/HJH.0b013e3283410390","article-title":"A functional variant of the nedd4l gene is associated with beneficial treatment response with beta-blockers and diuretics in hypertensive patients","volume":"29","author":"Wahlstrand","year":"2011","journal-title":"J. Hypertens."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/HYPERTENSIONAHA.109.135103","article-title":"A functional variant of NEDD4L is associated with hypertension; antihypertensive response; and orthostatic hypotension","volume":"54","author":"Luo","year":"2009","journal-title":"Hypertension"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1161\/01.HYP.0000178594.63193.c0","article-title":"Association of NEDD4L ubiquitin ligase with essential hypertension","volume":"46","author":"Russo","year":"2005","journal-title":"Hypertension"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Dahlberg, J., Nilsson, L.O., von Wowern, F., and Melander, O. (2007). Polymorphism in NEDD4L is associated with increased salt sensitivity; reduced levels of P-renin and increased levels of NT-pro-ANP. PLoS ONE, 2.","DOI":"10.1371\/journal.pone.0000432"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1097\/HJH.0b013e32835e2a71","article-title":"Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics","volume":"31","author":"McDonough","year":"2013","journal-title":"J. Hypertens."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/CIRCGENETICS.112.964080","article-title":"Hypertension susceptibility loci and blood pressure response to antihypertensives: Results from the pharmacogenomics evaluation of antihypertensive responses study","volume":"5","author":"Gong","year":"2012","journal-title":"Circ. Cardiovasc. Genet."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1097\/HJH.0000000000000541","article-title":"TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives","volume":"33","author":"Chittani","year":"2015","journal-title":"J. Hypertens."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/FPC.0000000000000353","article-title":"Targeted sequencing identifies a missense variant in the BEST3 gene associated with antihypertensive response to hydrochlorothiazide","volume":"28","author":"Singh","year":"2018","journal-title":"Pharmacogenet Genomics"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3390\/ph3061779","article-title":"The Pharmacogenomics of Anti-Hypertensive Therapy","volume":"3","author":"Padmanabhan","year":"2010","journal-title":"Pharmaceuticals"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.107.704023","article-title":"Ethnic differences in cardiovascular drug response: Potential contribution of pharmacogenetics","volume":"118","author":"Johnson","year":"2008","journal-title":"Circulation"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/13\/4709\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:46:00Z","timestamp":1760175960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/13\/4709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":119,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2020,7]]}},"alternative-id":["ijms21134709"],"URL":"https:\/\/doi.org\/10.3390\/ijms21134709","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]}}}